Co-amplification of HER2 and TOP2A serves as a sensitive indicator for selecting anthracycline-based chemotherapy for invasive breast cancer patients, who can benefit significantly from these treatments (82). This evidence concerns the gene ERBB2 and invasive breast carcinoma.